Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial / Agrati C.; Di Cosimo S.; Fenoglio D.; Apolone G.; Ciceri F.; Ciliberto G.; Baldanti F.; Costantini M.; Giannarelli D.; Ippolito G.; Locatelli F.; Mantovani A.; Morrone A.; Tagliavini F.; Uccelli A.; Zinzani P.L.; Silvestris N.; Rescigno M.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - ELETTRONICO. - 12:(2021), pp. 704110-704110. [10.3389/fimmu.2021.704110]

COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial

Zinzani P. L.;
2021

Abstract

Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials. However, this population may present immune response abnormalities, and relative reduced vaccine responsiveness. Here we review the limited current evidence on the immune responses to vaccination of patients with different underlying diseases. To address open questions we present the VAX4FRAIL study aimed at assessing immune responses to vaccination in a large transdisease cohort of patients with cancer, neurological and rheumatological diseases.
2021
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial / Agrati C.; Di Cosimo S.; Fenoglio D.; Apolone G.; Ciceri F.; Ciliberto G.; Baldanti F.; Costantini M.; Giannarelli D.; Ippolito G.; Locatelli F.; Mantovani A.; Morrone A.; Tagliavini F.; Uccelli A.; Zinzani P.L.; Silvestris N.; Rescigno M.. - In: FRONTIERS IN IMMUNOLOGY. - ISSN 1664-3224. - ELETTRONICO. - 12:(2021), pp. 704110-704110. [10.3389/fimmu.2021.704110]
Agrati C.; Di Cosimo S.; Fenoglio D.; Apolone G.; Ciceri F.; Ciliberto G.; Baldanti F.; Costantini M.; Giannarelli D.; Ippolito G.; Locatelli F.; Mantovani A.; Morrone A.; Tagliavini F.; Uccelli A.; Zinzani P.L.; Silvestris N.; Rescigno M.
File in questo prodotto:
File Dimensione Formato  
fimmu-12-704110.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 812.23 kB
Formato Adobe PDF
812.23 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/866853
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 18
social impact